Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study

Marianne S. Muhlebach, Joseph E. Hatch, Gisli G. Einarsson, Stef J. McGrath, Deirdre F. Gilipin, Gillian Lavelle, Bojana Mirkovic, Michelle A. Murray, Paul McNally, Nathan Gotman, Sonia Davis Thomas, Matthew C. Wolfgang, Peter H. Gilligan, Noel G. McElvaney, J. Stuart Elborn, Richard C. Boucher, Michael M. Tunney
European Respiratory Journal 2018 52: 1800242; DOI: 10.1183/13993003.00242-2018
Marianne S. Muhlebach
1Dept of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph E. Hatch
2Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
3Dept of Pediatrics, Indiana University, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gisli G. Einarsson
4Halo Research Group, School of Pharmacy, Queen's University Belfast, Belfast, UK
5Halo Research Group, Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stef J. McGrath
4Halo Research Group, School of Pharmacy, Queen's University Belfast, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deirdre F. Gilipin
4Halo Research Group, School of Pharmacy, Queen's University Belfast, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gillian Lavelle
6Respiratory Research Division, Dept of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bojana Mirkovic
6Respiratory Research Division, Dept of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bojana Mirkovic
Michelle A. Murray
6Respiratory Research Division, Dept of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul McNally
7Dept of Paediatrics, Royal College of Surgeons in Ireland, Our Lady's Children's Hospital Crumlin, Dublin, Ireland
8CF Research Group, National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paul McNally
Nathan Gotman
9Dept of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonia Davis Thomas
9Dept of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
10RTI International, Research Triangle Park, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew C. Wolfgang
2Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11Dept of Microbiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter H. Gilligan
12Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA
13Clinical Microbiology–Immunology Laboratories, UNC Health Care, Chapel Hill, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noel G. McElvaney
6Respiratory Research Division, Dept of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Stuart Elborn
5Halo Research Group, Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK
14Imperial College and Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard C. Boucher
2Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael M. Tunney
4Halo Research Group, School of Pharmacy, Queen's University Belfast, Belfast, UK
5Halo Research Group, Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Anaerobic and aerobic bacteria were quantitated in respiratory samples across three cystic fibrosis (CF) centres using extended culture methods. Subjects aged 1–69 years who were clinically stable provided sputum (n=200) or bronchoalveolar lavage (n=55). 18 anaerobic and 39 aerobic genera were cultured from 59% and 95% of samples, respectively; 16 out of 57 genera had a ≥5% prevalence across centres.

Analyses of microbial communities using co-occurrence networks in sputum samples showed groupings of oral, including anaerobic, bacteria, whereas typical CF pathogens formed distinct entities. Pseudomonas was associated with worse nutrition and F508del genotype, whereas anaerobe prevalence was positively associated with pancreatic sufficiency, better nutrition and better lung function. A higher total anaerobe/total aerobe CFU ratio was associated with pancreatic sufficiency and better nutrition. Subjects grouped by factor analysis who had relative dominance of anaerobes over aerobes had milder disease compared with a Pseudomonas-dominated group with similar proportions of subjects that were homozygous for F508del.

In summary, anaerobic bacteria occurred at an early age. In sputum-producing subjects anaerobic bacteria were associated with milder disease, suggesting that targeted eradication of anaerobes may not be warranted in sputum-producing CF subjects.

Abstract

Anaerobic bacteria are cultured across all ages, occur as communities and correlate with milder CF disease in adults http://ow.ly/7wQ430khMmE

Introduction

Antibiotic therapies for cystic fibrosis (CF) respiratory infections are targeted at specific bacteria, typically Staphylococcus aureus, Pseudomonas aeruginosa and other Gram-negative species. However, both culture-dependent and culture-independent molecular methods have redefined CF respiratory infections as polymicrobial, with a diverse lower airways bacterial community [1]. Anaerobic conditions have been described in CF lower airways [2, 3]. Importantly, obligate and facultative anaerobic bacteria, typically associated with the oral cavity, have been cultured in abundance from CF respiratory samples [4, 5]. Indeed, extended anaerobic culture methods identified anaerobic bacteria in high numbers in >60% of CF sputum samples from adults [6].

The role of anaerobic bacteria in CF lower airways disease is not clearly understood. Studies have identified anaerobic bacteria from direct lung samples, suggesting their presence does not simply reflect salivary contamination during sampling [7]. In vitro studies have demonstrated that anaerobes release virulence factors, including proteases and pro-inflammatory short-chain fatty acids [8, 9], suggesting that anaerobes may be pathogenic in the CF lung. In contrast, in vivo molecular studies indicate that greater anaerobe diversity is associated with milder disease [10, 11]. Molecular methods highlight the breadth of bacteria, and novel preparation methods and metagenomics address a shortcoming of conventional next-generation sequencing, i.e. the amplification of sequences of nonviable bacteria [12–14]. Bacterial abundance can be measured by quantitative PCR; however, 16S rRNA copy numbers per genome vary between genera and quantitation of different genera in multispecies infections remains imprecise [15, 16]. Culture allows enumeration of the different bacterial genera in a polymicrobial infection, demonstrates viability and growth in lower airways, and enables subsequent in vitro studies [17, 18]. Culturing anaerobic and bacteria not typically considered as pathogenic is also relevant to clinical care, i.e. would knowledge about abundance of these bacteria be useful for treatment?

Here, we assessed the association of strict anaerobes with disease severity in CF across all age ranges at three CF centres with different genetic and geographic backgrounds and medications. Although “CF pathogens” can grow under anaerobic conditions, this likely reflects adaptation to the microenvironment and not distinct genera/infections. We used extended culture methods attempting to investigate the role of anaerobes in CF lung disease. We focused on strict anaerobic bacteria to match genera reported in molecular studies, and to ascertain the load and viability of these anaerobes in lower airways in relation to typical CF pathogens. Three key questions were investigated. 1) Does the prevalence of anaerobes versus aerobes in subjects with CF change as a function of age and site/climate? 2) Are there associations between prevalence or quantity of anaerobes and genotype, disease severity and medications? 3) Are community structures established by anaerobes and do they differ across ages, disease severity or associations with aerobes?

Methods

Subjects and sample collection

People diagnosed with CF attending CF centres in Belfast in the UK (Adult and Paediatric CF Clinics, Belfast Health and Social Care Trust), University of North Carolina (UNC) at Chapel Hill, NC in the USA (UNC Hospital Pediatric and Adult Clinics) and Dublin in Ireland (Beaumont Hospital and Our Lady's Children's Hospital, Crumlin) were prospectively enrolled into this study between July 2010 and November 2013. Subjects who had undergone transplant, were taking CF transmembrane conductance regulator potentiators/modulators or enrolled in interventional therapeutic trials were excluded. Ethical approval for the study was obtained at each institution, and informed consent/assent was obtained from all adults, parents and paediatric subjects.

Either bronchoalveolar lavage (BAL) or sputum (if able to expectorate) and concomitant clinical information were collected when subjects were clinically stable, defined as not having received antibiotics beyond chronic maintenance therapy and ≥6 weeks post-completion of intravenous antibiotic therapy. Bronchoscopy was performed at UNC if a child had a procedure requiring anaesthesia and for routine surveillance at Dublin. At both sites, bronchoscopy was performed utilising a laryngeal mask airway or endotracheal tube.

Clinical data

Demographics, anthropometrics, lung function, medication history and disease complications were entered into a centralised database. Genotype was categorised by number of F508del alleles. Disease severity was assessed by nutritional status, pancreatic status and lung function (forced expiratory volume in 1 s (FEV1) % pred; see supplementary material) if subjects were able to reliably perform spirometry as per American Thoracic Society/European Respiratory Society criteria [19]. For comparisons of body mass index (BMI) across paediatric and adult age ranges, BMI was stratified into poor, acceptable and well-nourished categories based on percentiles in children (≤5%ile, 6–50%ile and >50%ile) and absolute BMI in adults [20].

Bacterial isolation and identification

Standardised culture protocols were used across the three sites as previously described [6], with further details provided in the supplementary material. Briefly, samples were treated for 15 min with dithiothreitol prior to serial dilution and plating on both selective and nonselective media (supplementary table S1). Plates were incubated under aerobic–micro-aerophilic and anaerobic conditions for between 2 and 7 days. All bacteria detected were quantified (CFU·g−1 or CFU·mL−1 in BAL) by total viable count. Each distinct colonial morphotype was identified by full-length 16S rRNA gene sequencing. Strict anaerobes were defined as bacteria known not to survive under atmospheric oxygen tension, whereas facultative anaerobic and aerobic bacteria that grew under anaerobic conditions were included as aerobes in all analyses.

Statistical analysis

Demographics, markers of disease severity and bacterial prevalence (presence of bacteria at any CFU >0) were compared across clinical sites using the Chi-squared or Fisher's exact test for categorical variables and the Mantel–Haenszel mean score Chi-squared test for ordinal variables. Associations between presence of bacteria and markers of disease severity were assessed by the Mantel–Haenszel mean score Chi-squared test. Analyses were stratified by site as described.

Multivariate logistic regression was used to test for factors that predict prevalence of specific bacterial genera. Predictors were identified via a stepwise model selection (with significance level for entry or staying in the model of p=0.10 or p=0.05, respectively).

Analyses that included bacterial quantities/density were log-transformed to account for nonnormal distributions using log10(CFU·g−1+1) to incorporate samples with no detectable bacteria. Bacterial diversity measures included richness (number of counted taxa), evenness and diversity (Shannon–Wiener index). Analyses of bacterial communities (network analyses and factor analysis) were conducted on sputum bacterial quantity for the most common genera. Co-occurrence (network analysis) between taxonomic groups was calculated as previously described [21]. Factor analysis as an unsupervised method to group genera was conducted using varimax rotations to achieve independent factor groupings. These factors were used to assign each subject to a group defined by their dominating factor based on similarity of bacterial quantities (see details in supplementary material).

Results

Subjects and samples

255 subjects were enrolled. Sputum samples (n=200) were obtained at all three sites, whereas BAL (n=55) samples were collected only at UNC (n=24) and Dublin (n=31). All samples from children aged <6 years were BAL (n=39). Either sputum (n=34) or BAL (n=12) were collected from subjects aged 6– <18 years; for subjects aged ≥18 years, 166 sputum and four BAL samples were collected.

Subject characteristics by site are shown in table 1. Site-specific differences in the study subjects included older age and fewer subjects positive for F508del mutations in Belfast compared with UNC or Dublin. Fewer subjects in Belfast were undernourished, and, despite being an older cohort, FEV1 values in Belfast were similar to those in UNC and Dublin, consistent with milder disease in Belfast. Use of chronic medications was lower in those contributing BAL versus sputum (supplementary table S2a and b).

View this table:
  • View inline
  • View popup
TABLE 1

Patient demographics by site

Prevalence and abundance of genera with age

18 anaerobic and 39 aerobic genera were cultured (supplementary table S3), representing 167 species (supplementary table S4). The prevalence of one or more strict anaerobic genus at any CFU >0 in a sample was 59% and was higher in sputum (67%) than BAL samples (31%) (p<0.001). Aerobic bacteria were present at any CFU >0 in 197 out of 200 (99%) of sputum and in 51 out of 55 (93%) BAL samples. The mean±sem total viable counts were higher for aerobic than anaerobic bacteria in sputum (2.27×108±3.80×107 versus 2.86×107±2.07×107 CFU·g−1; p<0.001) and BAL (3.97×107±3.71×107 versus 2.27×104±1.61×104 CFU·mL−1; p<0.001).

The ratio of anaerobic to aerobic viable counts for BAL and sputum showed no differences across age groups (supplementary figure S1a). Bacterial richness was lower in BAL (3.03±0.31) compared with sputum (5.18±0.16) (p<0.001), but similar within each sample type over age sextiles that approximate clinical progression (figure 1a). Shannon diversities showed similar trends (supplementary figure S1b). 16 genera that had a ≥5% prevalence across BAL and sputum samples are shown by age sextiles in supplementary table S5. The most prevalent anaerobic and aerobic genera across all ages were Prevotella (51%) and Streptococcus (82%), respectively. More prevalent bacteria were more abundant with the exception of Burkholderia with a 5% prevalence, but being most abundant when present, and Prevotella with high prevalence, but low abundance. Changes in prevalence of the most frequently cultured anaerobes and aerobes with age showed decreasing prevalence from childhood to mid-adulthood, with subsequent increases for anaerobic genera and Streptococcus. Inverse trends were seen for Pseudomonas (figure 1b).

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Changes in bacterial communities and prevalence with subject age: a) richness across age sextiles, and b) prevalence of anaerobes, aerobes and specific genera across age sextiles. BAL: bronchoalveolar lavage. a) Richness, defined as number of anaerobic and aerobic genera detected at any CFU >0 per sample, did not differ between age groups within sample types (BAL and sputum). Boxes indicate the 25th–75th quartiles with horizontal lines indicating the median; whiskers are 1.5 times the interquartile range. b) Prevalence for the most prevalent bacteria shown by age group. The number of samples for each group is given in parentheses. Bacterial density and prevalence were lower in BAL than sputum. Only BAL samples are included in subjects aged <6 years.

Analyses of samples by sites revealed differences in bacterial richness across sites, but similar diversity in sputum samples (supplementary figure S2a). There were no differences in richness or diversity in BAL samples from Dublin versus UNC (supplementary figure S2b). The prevalence of Pseudomonas was highest at UNC, with Burkholderia, Haemophilus, Actinomyces, Rothia and Gemella being more prevalent in Belfast. Neisseria prevalence was lowest in Belfast. Dublin had the lowest prevalence of Prevotella and Veillonella. Further details are shown by site and sample type in supplementary table S3 and supplementary figure S3.

Relationship between bacterial prevalence, abundance and disease severity

In subjects who produced sputum (n=200), anaerobes were associated with phenotypically milder disease, e.g. better lung function and BMI, and with pancreatic sufficiency, absence of insulin and chronic antibiotic use, but not genotype (figure 2a). Haemophilus influenzae, an aerobe observed in early CF disease, followed a similar pattern (figure 2b). Staphylococcus exhibited an intermediate pattern with negative associations, i.e. was less prevalent, with use of chronic antibiotics (figure 2c). The pattern for Pseudomonas, however, was distinctly different from anaerobes. Pseudomonas prevalence was positively associated with worse BMI, number of F508del alleles and chronic antibiotics (figure 2d).

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

Prevalence as percentage of subjects within the category with any CFU >0 for a) anaerobes, b) Haemophilus, c) Staphylococcus and d) Pseudomonas in sputum and their association with clinical characteristics. BMI: body mass index; FEV1: forced expiratory volume in 1 s; PS: pancreatic sufficiency; PI: pancreatic insufficiency; AZM: azithromycin. 200 sputum samples included. Seven subjects had missing data for FEV1 and eight subjects had missing data for BMI. BMI categories are 1: poor nutritional status; 2: adequate; 3: well nourished. FEV1 % pred categories are 1: <40%; 2: 40–80%; 3: >80% (see supplementary material). Numbers per category are given as percentage of subjects positive for this characteristic, where each category (e.g. “BMI 1”) can reach 100%. Inhaled antibiotics included tobramycin, colistin and aztreonam. *: significant difference between groups by the Mantel–Haenszel mean score Chi-squared test stratified by site.

Logistic regression adjusting for covariates with p<0.05 identified through stepwise modelling revealed a lower prevalence of anaerobes in pancreatic-insufficient subjects (table 2). With respect to aerobes, a lower prevalence of Haemophilus and Staphylococcus was associated with use of azithromycin. Pseudomonas prevalence again was associated with F508del alleles, and both azithromycin and inhaled antibiotic use. For BAL, clinical or site variables were not associated with bacterial prevalence.

View this table:
  • View inline
  • View popup
TABLE 2

Odds ratios from logistic regression models of bacterial prevalence in sputum

No associations were observed for absolute anaerobic or aerobic viable counts and clinical variables or study site in sputum or BAL. However, calculation of the anaerobe/aerobe CFU ratio showed that subjects with a relatively higher load of anaerobes had milder disease (pancreatic sufficiency and higher BMI) than aerobe-dominated subjects (supplementary figure S4).

Community structure in sputum and association with subject characteristics

Bacterial communities reflecting the 16 genera with a ≥5% prevalence were explored in sputum samples (n=200) using microbial co-occurrence network analysis. Bacteria typical of the oropharynx, e.g. Streptococcus, Rothia and Gemella, associated with each other. In contrast, Staphylococcus, Pseudomonas and Burkholderia each formed distinct entities (figure 3).

FIGURE 3
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3

Bacterial co-occurrence network between genera detected by extended microbial culture. The 16 genera detected at a ≥5% prevalence from sputum samples are contained within the network. Co-occurring microbial taxa are shown with nodes (circles) denoting a particular genus within the network and each edge (blue lines) denoting a significant co-occurrence relationship (Spearman's rank correlation coefficient) for positive correlations lines); adjusted p-value <0.05 (Benjamini–Hochberg–Yekutieli false discovery rate correction; see supplementary material). The size of the corresponding nodes demonstrates the relative proportion of each genus within the current study and the thickness of the edges represents the strength of the corresponding associations.

Next, factor analysis was used to reduce the complexity of the microbiota per sample into a set of variables that best defined sample community composition. The bacterial community compositions were generally consistent with the co-occurrence networks. Five components/factors explained 49% of the variation (figure 4). Factors 1 and 2 were dominated by oral-associated bacteria, including Streptococcus, Gemella and Rothia. Factor 3 included Haemophilus and Neisseria. Factor 4 was dominated by obligate anaerobes. Pseudomonas defined Factor 5, which was also negatively associated with Staphylococcus and Burkholderia.

FIGURE 4
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4

Loadings from factor analysis showing groupings of bacteria with each other based on quantity in sputum (n=200 samples). Five factors explain 49% of the total variation. Blue indicates positive associations and red indicates negative associations, with darker colours indicating the robustness of associations.

To define the clinical relevance of these microbial communities, patient sputum samples were defined by their dominating factor (table 3). Thus, each sample was assigned to Groups 1–5. There were no differences in pancreatic status, use of azithromycin, mucolytics and anaerobic or aerobic bacterial load/density between groups. Groups 4 and 5 had the highest percentage of F508del homozygous subjects, yet differed significantly with regard to both anaerobes and Pseudomonas. The group with higher anaerobic density/diversity (Group 4) tended to have a higher FEV1 and a lower incidence of poor nutritional status compared with the Pseudomonas-dominated Group 5. Notably, Group 3 included the fewest subjects with poor nutritional status and the most with a high FEV1, compared with other groups, but had the highest proportion of subjects aged <20 years.

View this table:
  • View inline
  • View popup
TABLE 3

Patient characteristics within the groups characterised by bacterial communities identified by factor analysis

Discussion

Anaerobic and aerobic bacteria were cultured from respiratory samples across all age ranges to assess bacterial prevalence and quantify density in CF respiratory secretions. The prevalence and quantities of both anaerobic and aerobic bacteria were lower in BAL compared with sputum. Interestingly, the anaerobe/aerobe ratios in BAL, i.e. incorporating quantity, were similar to sputum. Facultative anaerobes and micro-aerophilic bacteria were also cultured in both sample types (supplementary table S3) and were included with aerobes, potentially underestimating the true anaerobic burden in the CF lung. Pseudomonas and Staphylococcus also grow anaerobically, a growth mode associated with persistence in chronic infection, but the focus in this study was on strict anaerobes as determined in molecular studies. The prevalence of anaerobes and Streptococcus declined from early childhood to early adulthood, i.e. a time when many patients experience worsening disease. In older age groups, anaerobes were more prevalent again, possibly related to less severe disease (figure 1b) as reflected by the higher anaerobe/aerobe ratio in subjects with better nutritional status (supplementary figure S4). Anaerobic and streptococcal species are highly abundant in oral secretions, and are detected in the oral cavity in the first months of life [22]. Although oral secretions are a source of contamination of sputum and BAL, the high abundance of anaerobic genera makes sample contamination an unlikely explanation for our findings. Although BAL samples were obtained via a laryngeal mask airway or endotracheal tube, which decreases the risk of contamination, the lower anaerobe prevalence in BAL compared with sputum likely reflects the younger BAL subject age with lower bacterial load and sample dilution. Aerobe prevalence and abundance were also lower in BAL than sputum. Typically, BAL is assumed to represent a 30- to 80-fold dilution of epithelial lining fluid [23, 24].

The source of CF lower airways oral bacteria likely reflects micro-aspiration as reported in healthy subjects, in whom oral bacteria are found in proximal airways but continuous mucociliary clearance prevents growth to high densities [25, 26]. We suggest that starting in infancy, abnormal mucociliary clearance in CF enhances retention of aspirated flora in an anaerobic airways environment, allowing anaerobic bacteria to proliferate. Such a scenario is consistent with recent CF infant BAL microbiome analyses [27–29].

The contribution of anaerobic bacteria to lung disease is not clearly understood. This large study, which analysed samples from 255 CF subjects across three sites and a wide age range, characterised the anaerobic and aerobic microbial community composition in the CF airways using extended culture methods. A prior molecular study had shown geographical differences in the CF microbiome [30]. In our study, differences occurred by study site but not by continent, making climate a less relevant factor than genotype (e.g. F508del) and associated disease severity. We observed that anaerobic bacteria were more prevalent in sputum of subjects with milder disease. Higher lung function, increased BMI, pancreatic sufficiency and absence of requirement for insulin were associated with higher prevalence of anaerobes in univariate analyses (figure 2). Lower prevalence of anaerobes and Haemophilus in subjects on azithromycin could be due to the antibacterial activity of azithromycin. Azithromycin exhibits good activity against those organisms in non-CF disease; however, high rates of resistance are seen in CF that may mitigate its activity [31, 32]. Notably, associations with pancreatic sufficiency remained significant when adjusting for multiple medications and clinical parameters (table 2). A sensitivity analyses with p=0.1 for staying in the model additionally included FEV1 for Pseudomonas, azithromycin and insulin for anaerobes, and hypertonic saline for Haemophilus (supplementary table S6).

Our culture-based findings are consistent with observations from molecular microbiome studies describing higher diversity with less severe CF lung disease [5, 33] and decreasing diversity in patients with more rapid lung function decline [5, 11]. Our quantitative cultures allowed these relationships to be extended to anaerobic and aerobic bacterial density, anaerobe/aerobe ratio and diversity. A higher anaerobe/aerobe ratio was associated with pancreatic sufficiency and better nutrition, with trends for higher lung function in those with a higher anaerobe/aerobe ratio (supplementary figure S4). However, associations between absolute aerobic or anaerobic bacterial concentrations/density and FEV1 were not detected. We hypothesise that the absence of such an association partly reflects the spatial heterogeneity of CF lung disease, with bacterial density reflecting disease severity in focal bronchiectatic areas, whereas FEV1 reflects the overall extent of diseased lung. The hypothesis that FEV1 is not sufficiently sensitive to detect regional, bronchiectatic disease is supported by a study that reported associations between anaerobic density in CF patients and lung clearance index, but not FEV1 [34]. Moreover, it should be noted that age-based CF-specific lung function parameters developed for children [35] are not available for adults and effects of genetic mutations on lung function were not included. Thus, although we used Global Lung Initiative reference equations (see supplementary material) for comparison across body stature and centre, analyses of relationships of bacterial density with FEV1 may have been more sensitive if CF- and age-specific references were available.

Analyses of anaerobe pathogenicity in vitro may also yield insight into the relationships between anaerobes and CF disease severity. Prevotella was the most abundant and prevalent anaerobic genus in this study, and has been reported consistently in other studies [5, 6, 10, 36–38]. In vitro studies of laboratory strains of Prevotella demonstrated that they produce short-chain fatty acids and proteases that may be pro-inflammatory [9]. However, Prevotella elicits diminished pro-inflammatory responses in respiratory cell lines and murine models compared with classic aerobic pathogens [39]. Thus, conceivably the relatively lower virulence of anaerobes contributes to their association with a milder CF phenotype.

Co-occurrence networks to visualise potential bacterial interactions showed groupings of orally derived anaerobic bacteria, which occupied niches distinct from the known pathogens (e.g. Pseudomonas and Staphylococcus) that were themselves highly dissimilar (figure 3). Both Burkholderia and Pseudomonas release products that are toxic to other bacteria, which may contribute to their distinct niches as well as their dominance [40]. CF registry data also demonstrate decreasing prevalence of Staphylococcus in older patients as Pseudomonas prevalence increases, suggesting a similar community competition for these two bacteria [41, 42].

Factor analyses (figure 4) revealed bacterial groupings similar to the co-occurrence networks. These factors enabled testing of associations with clinical parameters based on samples defined by the highest factor loadings (table 3). Group 4 with the highest prevalence and diversity of anaerobes had milder disease than the Pseudomonas-dominated group, but not the mildest disease, possibly reflecting that Group 4 exhibited the highest proportion of F508del homozygote subjects and moderate/high rates of Pseudomonas.

A challenge to the present study is the inclusion of paediatric and adult age groups, necessitating comparisons between BAL and sputum. For age-wide comparisons, prevalence was used as a surrogate in addition to the ratio of anaerobic to aerobic bacterial load. Similar to prior studies, this study is limited by its observational design and thus cannot determine the association versus causality with respect to anaerobe-induced disease severity. This difference has an impact when considering targeted anaerobe antibiotic therapy in subjects with CF. A recent study in infants with CF demonstrated more airway inflammation in children whose airway microbiome was dominated by anaerobes compared with “sterile” airways [29]. Anaerobes may also condition the lower CF airways to promote infection with more classic pathogens [43]. Such data may support treatment of anaerobes in early CF disease. In contrast, bacterial culture and molecular studies in older, sputum-producing subjects suggest that a diverse lung microbiota with relatively abundant anaerobes is associated with milder disease. Conceivably, higher anaerobic diversity in adults with milder disease reflects lower antibiotic use in such subjects [44] and/or lower intrinsic virulence of anaerobes [39]. Therefore, targeted “eradication” of anaerobes in older patients, when clinically at baseline, might result in little clinical benefit and more resistant organisms. Anaerobes may increase at onset of exacerbations and therefore their role may fluctuate with short-term changes in disease state [6, 14]. Anaerobes are not routinely cultured for in the clinical setting. This approach may be justified in older subjects if antimicrobial therapy is not being considered.

In summary, anaerobic bacteria were detected in CF respiratory secretions at all ages. In the age groups investigated in this study, aerobes dominated over anaerobes with respect to bacterial numbers. The prevalence of anaerobic genera was associated with milder disease and lower use of antibiotics, suggesting that a diverse anaerobic microbiota may be a marker of better health in older subjects with CF. Sputum anaerobic/aerobic bacterial genera clustered into communities, which were associated with clinical outcomes. Cross-sectional studies do not permit the distinction of anaerobes as markers versus causative factors in the severity of lung disease. Collectively, our data suggest that targeted eradication of anaerobes in the context of aerobic pathogenic bacteria may not be warranted until further data are available.

Supplementary material

Supplementary Material

Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

Supplementary material ERJ-00242-2018_Supplement

Acknowledgements

We would like to thank the patients and families who participated in this study, and the clinical teams at each site who facilitated completion of the study. We acknowledge all staff involved in laboratory culture of bacteria and patient recruitment.

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • Conflict of interest: G.G. Einarsson's work is supported by a grant from IMI (iABC; Inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis). N. Gotman reports grants from AECF, during the conduct of the study. S. Davis Thomas reports grants from the National Institutes of Health (NIH), during the conduct of the study. P.H. Gilligan reports grants from the NIH, during the conduct of the study. M.C. Wolfgang reports grants from the NIH, during the conduct of the study. J.S. Elborn reports grants from Northern Ireland Research and Development, during the conduct of the study. R.C. Boucher is Chairman of the Board of Parion Sciences, a privately held UNC spin-out company focused on developing therapies for CF, and has received monetary compensation for this role. M.M. Tunney reports grants from Health and Social Care Research and Development Division, Public Health Agency, Northern Ireland, during the conduct of the study; and grants from Alaxia, outside the submitted work.

  • Support statement: Work at UNC was supported by the National Institutes of Health (NIH) under grants HL084934, HL100809, P30DK065988 and P0HL108808. Research at Queen's University Belfast was funded by the Health and Social Care Research and Development Division, Public Health Agency, Northern Ireland and the Medical Research Council through a US–Ireland Partnership Grant. M.M. Tunney was supported by a Health and Social Care Research and Development, Public Health Agency, Northern Ireland-funded UK National Institute for Health Research Career Scientist Award. Research at Royal College of Surgeons in Ireland, Dublin was supported by the Science Foundation Ireland and the Health Research Board under grant SFI/08/US/B1676 and by the NIH under grant 5R01 HL092964-04. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received February 6, 2018.
  • Accepted May 24, 2018.
  • Copyright ©ERS 2018

References

  1. ↵
    1. Sherrard LJ,
    2. Tunney MM,
    3. Elborn JS
    . Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. Lancet 2014; 384: 703–713.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Worlitzsch D,
    2. Tarran R,
    3. Ulrich M, et al.
    Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002; 109: 317–325.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Cowley ES,
    2. Kopf SH,
    3. LaRiviere A, et al.
    Pediatric cystic fibrosis sputum can be chemically dynamic, anoxic, and extremely reduced due to hydrogen sulfide formation. MBio 2015; 6: e00767.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Worlitzsch D,
    2. Rintelen C,
    3. Bohm K, et al.
    Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin Microbiol Infect 2009; 15: 454–460.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Coburn B,
    2. Wang PW,
    3. Diaz Caballero J, et al.
    Lung microbiota across age and disease stage in cystic fibrosis. Sci Rep 2015; 5: 10241.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Tunney MM,
    2. Field TR,
    3. Moriarty TF, et al.
    Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008; 177: 995–1001.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Brown PS,
    2. Pope CE,
    3. Marsh RL, et al.
    Directly sampling the lung of a young child with cystic fibrosis reveals diverse microbiota. Ann Am Thorac Soc 2014; 11: 1049–1055.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Ghorbani P,
    2. Santhakumar P,
    3. Hu Q, et al.
    Short-chain fatty acids affect cystic fibrosis airway inflammation and bacterial growth. Eur Respir J 2015; 46: 1033–1045.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Mirkovic B,
    2. Murray MA,
    3. Lavelle GM, et al.
    The role of short-chain fatty acids, produced by anaerobic bacteria, in the cystic fibrosis airway. Am J Respir Crit Care Med 2015; 192: 1314–1324.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Cox MJ,
    2. Allgaier M,
    3. Taylor B, et al.
    Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS One 2010; 5: e11044.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Zhao J,
    2. Schloss PD,
    3. Kalikin LM, et al.
    Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci USA 2012; 109: 5809–5814.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Young GR,
    2. Smith DL,
    3. Embleton ND, et al.
    Reducing viability bias in analysis of gut microbiota in preterm infants at risk of NEC and sepsis. Front Cell Infect Microbiol 2017; 7: 237.
    OpenUrl
    1. Nguyen LD,
    2. Deschaght P,
    3. Merlin S, et al.
    Effects of propidium monoazide (PMA) treatment on mycobiome and bacteriome analysis of cystic fibrosis airways during exacerbation. PLoS One 2016; 11: e0168860.
    OpenUrlCrossRef
  13. ↵
    1. Lim YW,
    2. Evangelista JS III.,
    3. Schmieder R, et al.
    Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis. J Clin Microbiol 2014; 52: 425–437.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Klappenbach JA,
    2. Saxman PR,
    3. Cole JR, et al.
    rrndb: the Ribosomal RNA Operon Copy Number Database. Nucleic Acids Res 2001; 29: 181–184.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Vetrovsky T,
    2. Baldrian P
    . The variability of the 16S rRNA gene in bacterial genomes and its consequences for bacterial community analyses. PLoS One 2013; 8: e57923.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Sherrard LJ,
    2. Schaible B,
    3. Graham KA, et al.
    Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in Prevotella isolated from cystic fibrosis (CF) and non-CF patients. J Antimicrob Chemother 2014; 69: 2690–2698.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Sherrard LJ,
    2. McGrath SJ,
    3. McIlreavey L, et al.
    Production of extended-spectrum beta-lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiota. Int J Antimicrob Agents 2016; 47: 140–145.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Laszlo G
    . Standardisation of lung function testing: helpful guidance from the ATS/ERS Task Force. Thorax 2006; 61: 744–746.
    OpenUrlFREE Full Text
  19. ↵
    1. Turck D,
    2. Braegger CP,
    3. Colombo C, et al.
    ESPEN–ESPGHAN–ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr 2016; 35: 557–577.
    OpenUrlCrossRef
  20. ↵
    1. Einarsson GG,
    2. Comer DM,
    3. McIlreavey L, et al.
    Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers. Thorax 2016; 71: 795–803.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Kononen E
    . Development of oral bacterial flora in young children. Ann Med 2000; 32: 107–112.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Singh S,
    2. Grover V,
    3. Christie L, et al.
    A comparative study of bronchoscopic microsample probe versus bronchoalveolar lavage in patients with burns-related inhalational injury, acute lung injury and chronic stable lung disease. Respiration 2015; 89: 19–26.
    OpenUrl
  23. ↵
    1. Braun J,
    2. Mehnert A,
    3. Dalhoff K, et al.
    Different BALF protein composition in normal children and adults. Respiration 1997; 64: 350–357.
    OpenUrlPubMed
  24. ↵
    1. Dickson RP,
    2. Erb-Downward JR,
    3. Freeman CM, et al.
    Spatial variation in the healthy human lung microbiome and the adapted island model of lung biogeography. Ann Am Thorac Soc 2015; 12: 821–830.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Bassis CM,
    2. Erb-Downward JR,
    3. Dickson RP, et al.
    Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. MBio 2015; 6: e00037.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Subbarao P,
    2. Milla C,
    3. Aurora P, et al.
    Multiple-breath washout as a lung function test in cystic fibrosis. A Cystic Fibrosis Foundation Workshop Report. Ann Am Thorac Soc 2015; 12: 932–939.
    OpenUrlCrossRefPubMed
    1. Frayman KB,
    2. Armstrong DS,
    3. Carzino R, et al.
    The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis. Thorax 2017; 72: 1104–1112.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Muhlebach MS,
    2. Zorn BT,
    3. Esther CR, et al.
    Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children. PLoS Pathog 2018; 14: e1006798.
    OpenUrl
  28. ↵
    1. Stressmann FA,
    2. Rogers GB,
    3. Klem ER, et al.
    Analysis of the bacterial communities present in lungs of patients with cystic fibrosis from American and British centers. J Clin Microbiol 2011; 49: 281–291.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Farrell DJ,
    2. Flamm RK,
    3. Sader HS, et al.
    Results from the Solithromycin International Surveillance Program (2014). Antimicrob Agents Chemother 2016; 60: 3662–3668.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Sherrard LJ,
    2. Graham KA,
    3. McGrath SJ, et al.
    Antibiotic resistance in Prevotella species isolated from patients with cystic fibrosis. J Antimicrob Chemother 2013; 68: 2369–2374.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Fodor AA,
    2. Klem ER,
    3. Gilpin DF, et al.
    The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One 2012; 7: e45001.
    OpenUrlCrossRefPubMed
  32. ↵
    1. O'Neill K,
    2. Bradley JM,
    3. Johnston E, et al.
    Reduced bacterial colony count of anaerobic bacteria is associated with a worsening in lung clearance index and inflammation in cystic fibrosis. PLoS One 2015; 10: e0126980.
    OpenUrl
  33. ↵
    1. Kulich M,
    2. Rosenfeld M,
    3. Campbell J, et al.
    Disease-specific reference equations for lung function in patients with cystic fibrosis. Am J Respir Crit Care Med 2005; 172: 885–891.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. Tunney MM,
    2. Klem ER,
    3. Fodor AA, et al.
    Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 2011; 66: 579–584.
    OpenUrlAbstract/FREE Full Text
    1. Zemanick ET,
    2. Wagner BD,
    3. Robertson CE, et al.
    Airway microbiota across age and disease spectrum in cystic fibrosis. Eur Respir J 2017; 50: 1700832.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Harris JK,
    2. De Groote MA,
    3. Sagel SD, et al.
    Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci USA 2007; 104: 20529–20533.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Larsen JM,
    2. Musavian HS,
    3. Butt TM, et al.
    Chronic obstructive pulmonary disease and asthma-associated Proteobacteria, but not commensal Prevotella spp., promote Toll-like receptor 2-independent lung inflammation and pathology. Immunology 2015; 144: 333–342.
    OpenUrlCrossRefPubMed
  37. ↵
    1. de la Fuente-Nunez C,
    2. Reffuveille F,
    3. Fernandez L, et al.
    Bacterial biofilm development as a multicellular adaptation: antibiotic resistance and new therapeutic strategies. Curr Opin Microbiol 2013; 16: 580–589.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Cystic Fibrosis Foundation
    . Patient Registry Annual Report. 2013. www.cff.org/2013_CFF_Patient_Registry_Annual_Data_Report.pdf Date last accessed: May 31, 2018.
  39. ↵
    1. UK Cystic Fibrosis Registry
    . Annual Report. 2015. www.cysticfibrosis.org.uk/the-work-we-do/uk-cf-registry Date last accessed: January 31, 2018.
  40. ↵
    1. Flynn JM,
    2. Niccum D,
    3. Dunitz JM, et al.
    Evidence and role for bacterial mucin degradation in cystic fibrosis airway disease. PLoS Pathog 2016; 12: e1005846.
    OpenUrlCrossRef
  41. ↵
    1. Zhao J,
    2. Murray S,
    3. Lipuma JJ
    . Modeling the impact of antibiotic exposure on human microbiota. Sci Rep 2014; 4: 4345.
PreviousNext
Back to top
View this article with LENS
Vol 52 Issue 1 Table of Contents
European Respiratory Journal: 52 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study
Marianne S. Muhlebach, Joseph E. Hatch, Gisli G. Einarsson, Stef J. McGrath, Deirdre F. Gilipin, Gillian Lavelle, Bojana Mirkovic, Michelle A. Murray, Paul McNally, Nathan Gotman, Sonia Davis Thomas, Matthew C. Wolfgang, Peter H. Gilligan, Noel G. McElvaney, J. Stuart Elborn, Richard C. Boucher, Michael M. Tunney
European Respiratory Journal Jul 2018, 52 (1) 1800242; DOI: 10.1183/13993003.00242-2018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study
Marianne S. Muhlebach, Joseph E. Hatch, Gisli G. Einarsson, Stef J. McGrath, Deirdre F. Gilipin, Gillian Lavelle, Bojana Mirkovic, Michelle A. Murray, Paul McNally, Nathan Gotman, Sonia Davis Thomas, Matthew C. Wolfgang, Peter H. Gilligan, Noel G. McElvaney, J. Stuart Elborn, Richard C. Boucher, Michael M. Tunney
European Respiratory Journal Jul 2018, 52 (1) 1800242; DOI: 10.1183/13993003.00242-2018
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original articles

  • Ambulatory management of secondary spontaneous pneumothorax
  • Systematic assessment of respiratory health in illness susceptible athletes
  • Identifying early PAH biomarkers in systemic sclerosis
Show more Original articles

Cystic fibrosis and bronchiectasis

  • Mucin bundles and cholinergic stimulation in cystic fibrosis
  • Immunological corollary of the pulmonary mycobiome in bronchiectasis
  • Air pollution: impact on bronchiectasis pulmonary exacerbation
Show more Cystic fibrosis and bronchiectasis

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society